# Supreme Life

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/supreme-life

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.supremelife.cn
- Latest round: Series A (Jan 26, 2026)
- Investors on record: 1

## About

Supreme Life, based in Beijing, China, specializes in innovative diabetes management solutions, focusing on advanced therapies and patient education to enhance care for individuals living with diabetes.Founded in 2020, Beijing Jingyihe Biomedical Technology Co., Ltd. operates primarily in diabetes management. The company has completed a total of 1 deal, with its most recent deal occurring on January 26, 2026. The founder's history is not explicitly documented, nor are there indications of prior ventures.Beijing Jingyihe Biomedical Technology Co., Ltd. specializes in diabetes management solutions, with a focus on innovative therapies that extend beyond traditional insulin and hypoglycemic treatments. Their core product offerings are designed to enhance patient care by integrating scientific education and patient case studies into their service model, thereby addressing the multifaceted needs of individuals living with diabetes. The company serves a diverse client base, including healthcare providers, clinics, and patients directly, primarily in urban centers across China and potentially in select international markets. By leveraging advanced research and patient-centric foundations, the company aims to empower users with tools and knowledge to manage their condition effectively, promoting better health outcomes through improved therapeutic options.The revenue structure of Beijing Jingyihe Biomedical Technology Co., Ltd. is built on direct-to-consumer and B2B models, engaging healthcare providers in partnerships to distribute their diabetes management products. Transactions typically involve subscription-based services for ongoing support and education, along with one-time purchases of proprietary devices or therapeutic products. This multi-faceted approach allows the company to establish long-term relationships with clients, ensuring a steady revenue stream. Specific pricing plans are aligned with the value provided, reflecting the advanced nature of the offerings that cater to both individual patients and healthcare institutions. The company’s flagship products position it competitively within the diabetes care market, emphasizing the importance of comprehensive support systems for effective disease management.In January 2026, Supreme Life raised an undisclosed amount of Series A+ funding from new investor CITIC Med Fund. This round of financing will be used to expand treatment centers, strengthen the research and development of AI-assisted traditional Chinese medicine diagnostic and treatment systems, and cultivate young traditional Chinese medicine professionals. The company aims to launch new products focused on enhancing diabetes management by mid-2026 and plans to expand into international markets, specifically targeting Southeast Asia and Europe by the end of 2027.

## Funding rounds

- Series A, Jan 26, 2026 — CITIC Med Fund

## Investors

- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series A